Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study
Titel:
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study
Auteur:
Iyer, Swaminathan P Sica, R Alejandro Ho, P Joy Prica, Anca Zain, Jasmine Foss, Francine M Hu, Boyu Beitinjaneh, Amer Weng, Wen-Kai Kim, Youn H Khodadoust, Michael S Huen, Auris O Williams, Leah M Ma, Anna Huang, Elaine Ganpule, Avanti Nagar, Shashwat Deepali Sripakdeevong, Parin Cullingford, Erika L Karnik, Sushant Dequeant, Mary-Lee Patel, Janki N He, Xinyi Shirley Li, Ziliang He, Qiuling Ally Mendonez, Joy H Keegan, Alissa Horwitz, Steven M